These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9617534)

  • 1. Metabolic interrelationships, cardiovascular disease, and sex steroids.
    Fotherby K
    Contraception; 1998 Mar; 57(3):183-7. PubMed ID: 9617534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation and anticoagulation effects of contraceptive steroids.
    Samsioe G
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1523-7. PubMed ID: 8178901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptives.
    Sheu WH; Hsu CH; Chen YS; Jeng CY; Fuh MM
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):249-55. PubMed ID: 8137525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the new progestogens in combination oral contraceptives.
    Rebar RW; Zeserson K
    Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism.
    Crook D; Godsland I
    Contraception; 1998 Mar; 57(3):189-201. PubMed ID: 9617535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.
    Petersen KR; Kjems LL; Skouby SO; Andersen LF; Jespersen J
    Metabolism; 1996 Jul; 45(7):833-7. PubMed ID: 8692017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective.
    Upton GV
    Fertil Steril; 1990 Jan; 53(1):1-12. PubMed ID: 2403935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
    Kelleher CC
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):392-5. PubMed ID: 2196811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New progestogens in oral contraception.
    Fotherby K; Caldwell AD
    Contraception; 1994 Jan; 49(1):1-32. PubMed ID: 8137623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normotensive women.
    Straznicky NE; Barrington VE; Branley P; Louis WJ
    J Hypertens; 1998 Mar; 16(3):357-68. PubMed ID: 9557929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex hormones and cardiovascular risk.
    L'Hermite M
    Acta Cardiol; 1991; 46(3):357-72. PubMed ID: 1927164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC; Hellberg D; Nilsson S; von Schoulz B; Crona N; Siegbahn A
    Contraception; 1994 Aug; 50(2):153-65. PubMed ID: 7956214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.